Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 219-224

  Catarino, Cristina ^a,b   Rebelo, Irene ^a,b   Belo, Luís ^a,b   Rocha, Susana ^a,b   Castro, Elisabeth B ^a,b   Patricio, Belmiro ^c,d   Quintanilha, Alexandre ^a,b   Santos Silva, Alice ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Endothelial dysfunction; PAI 1; Preeclampsia; Pregnancy; tPA

Indexed keywords

D DIMER; FIBRIN DEGRADATION PRODUCT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BIRTH WEIGHT; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HEMOSTASIS; HUMAN; MATERNAL BLOOD; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; UMBILICAL CORD BLOOD;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FETAL BLOOD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; INFANT, NEWBORN; MOTHERS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRE-ECLAMPSIA; PREGNANCY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 55549116017     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.007     Document Type: Article

References (23)

1. Stirling Y., Woolf L., North W.R.S., Seghatchian M.J., and Meade T.W. Haemostasis in normal pregnancy. Thromb Haemost 52 (1984) 176-182
2. Åstedt B. The placenta and haemostatic balance. In: Redman C.W.G., Sargent I.L., and Starkey P.M. (Eds). The human placenta (1993), Blackwell, Oxford 291-309
3. Higgins J.R., Walshe J.J., Darling M.R.N., Norris L., and Bonnar J. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 179 (1998) 520-526
4. Clark P., Brennand J., Conkie J.A., McCall F., Greer I.A., and Walker I.D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 79 (1998) 1166-1170
5. Declerck P.J., Alessi M.C., Verstreken M., Kruithof E.K.O., Juhan-Vague I., and Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71 (1988) 220-225
6. Estelles A., Gilabert J., Aznar J., Loskutoff D.J., and Schleef R.R. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 74 (1989) 1332-1338
7. Cadroy Y., Grandjean H., Pichon J., Desprats R., Berrebi A., Fournie A., et al. Evaluation of six markers of hemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 100 (1993) 416-420
8. Halligan A., Bonnar J., Sheppard B., Darling M., and Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 101 (1994) 488-492
9. Belo L., Santos-Silva A., Rumley A., Lowe G., Pereira-Leite L., Quintanilha A., et al. Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria. Br J Obstet Gynaecol 109 (2002) 1250-1255
10. Sattar N., Greer I.A., Rumley A., Stewart G., Shepherd J., Packard C.J., et al. A longitudinal study of the relationships between haemostatic, lipid, and oestradiol changes during normal human pregnancy. Thromb Haemost 81 (1999) 71-75
11. Roberts J.M. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 16 (1998) 5-15
12. Robson S.C. Hypertension and renal disease in pregnancy, pp. 166-185. In: Edmonds D.K. (Ed). Dewhurst's textbook of obstetrics and gynaecology for postgraduates. 6th ed (1999), Blackwell, Oxford
13. Estelles A., Gilabert J., España F., Aznar J., and Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 165 (1991) 138-142
14. Friedman S.A., Schiff E., Emeis J.J., Dekker G.A., and Sibai B.M. Biochemical corroboration of endothelial involvement in severe preeclampsia. Am J Obstet Gynecol 172 (1995) 202-203
15. Roes E., Sweep C., Thomas C., Zusterzeel P., Geurts-Moespot A., Peters W., et al. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Am J Obstet Gynecol 187 (2002) 1019-1025
16. Brown M.A., Lindheimer M.D., De Swiet M., Van Assche A., and Moutquin J.M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 20 1 (2001) ix-xiv
17. Rodrigues T., Teles T., Miguel C., Pereira A., and Barros H. Small for date. Role of birthweight reference charts in the prevalence of the condition and risk estimate. Acta Médica Portuguesa 9 (1996) 335-340
18. Higgins J., Bonnar J., Norris L., Darling M., and Walshe J. The effect of pre-eclampsia on coagulation and fibrinolytic activation in the neonate. Thromb Res 99 (2000) 567-570
19. Murtha A.P., Bogges K.A., Jimmerson C.E., Greig P.C., and Herbert W.N. Umbilical venous d-dimer concentrations with and without labor. Obstet Gynecol 92 2 (1998) 184-186
20. Levine R., Lam C., Qian C., Yu K., Maynard S., Sachs B., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
21. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 6 (2006) 642-649
22. Barron W.M., Heckerling P., Hibbard J.U., and Fisher S. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol 94 (1999) 364-370
23. Kobayashi T., Tokunaga N., Sugimura M., Suzuki K., Kanayama N., Nishiguchi T., et al. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 25 (1999) 451-454